ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 37 of 200 for:    Recruiting, Not yet recruiting, Available Studies | "Cystic Fibrosis"

A Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF) (HOME-CF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02994706
Recruitment Status : Recruiting
First Posted : December 16, 2016
Last Update Posted : February 27, 2018
Sponsor:
Collaborators:
National Institute for Health Research, United Kingdom
University of Birmingham
Information provided by (Responsible Party):
Heart of England NHS Trust

Brief Summary:

Cystic fibrosis (CF) is the most common fatal inherited condition in Caucasians, causing recurrent chest infections and premature death due to lung failure. When patients develop chest infections their symptoms usually slowly worsen over the course of several days to weeks. Due to this gradual onset, patients often seek medical attention several days or weeks after symptoms start to worsen. The Investigators believe that if they were able to monitor patients more closely they could diagnose and treat chest infections earlier and consequently improve health outcomes.

The HOMECF study aims to investigate whether home monitoring is beneficial for adults with CF. 100 subjects will be randomly allocated, 50 to receive home monitoring and 50 to receive routine clinical care for 12 months. Subjects receiving home monitoring will measure their lung function and symptoms twice weekly and this data will be transmitted to the medical team by means of a modified mobile phone.

the Investigators hypothesize that home monitoring will allow them to diagnose chest infections at an earlier stage and reduce hospital inpatient days. They will also assess the subjects' experience of receiving home monitoring, the impact on body weight and lung function and and conduct a full health economic analysis to assess value for money. They will also ask subjects to collect a urine sample once weekly to allow us to measure urinary levels of inflammatory markers.

Subjects will be recruited at the West Midlands Adult CF Centre in Birmingham. The research team are well placed to carry out the study because it is a large regional adult CF centre with an excellent record of conducting clinical research.


Condition or disease Intervention/treatment Phase
Cystic Fibrosis Procedure: Home Monitoring Other: Clinical Care Not Applicable

Detailed Description:

The principal question being answered by this research study is:

1. Does home monitoring reduce the total number of inpatient hospital days in adults with cystic fibrosis (CF) compared to routine clinical care?

The secondary objectives of this research study are to assess:

  1. The effect of home monitoring on lung function in adults with cystic fibrosis (CF)
  2. The effect of home monitoring on requirement for antibiotics in adults with CF
  3. The effect of home monitoring on nutritional status in adults with CF
  4. The effect of home monitoring on health related quality of life in adults with CF
  5. Costeffectiveness analysis comparing the home monitoring period with the routine clinical care period
  6. The patient experience of receiving home monitoring in adults with CF
  7. Whether urine levels of inflammatory markers correlate with symptoms and lung function in adults with CF

The aim of this study is assess whether home monitoring is beneficial for adults with cystic fibrosis. Overall, 100 subjects will be recruited at the West Midlands Adult Centre and randomly allocated in a 1:1 ratio to receive home monitoring or routine clinical care for 12 months.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: A Prospective Pilot Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF)
Study Start Date : January 2006
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Experimental: Home monitoring
Home monitoring will involve participants recording their symptoms twice weekly on a modified mobile phone and recording their lung function twice weekly using a digital spirometer. This data will be automatically transmitted to the CF team and we will contact patients on the mobile phone if symptoms and/or lung function decline below a set threshold, suggesting the onset of a pulmonary exacerbation. We will contact patients within 24 hours of symptoms and/or lung function falling below this set threshold.
Procedure: Home Monitoring
Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.

Active Comparator: Clinical Care
Throughout the study period, participants will attend outpatient clinic visits as usual and treatment with antibiotics as clinically indicated.
Other: Clinical Care
Participants selected for this arm will continue to receive routine clinical care.




Primary Outcome Measures :
  1. Number of inpatient hospital days in the home monitoring group compared to the routine clinical care group [ Time Frame: up to 12 months ]

Secondary Outcome Measures :
  1. Change in FEV1 in the home monitoring group compared to the routine clinical care group [ Time Frame: up to 12 months ]
  2. Change in FVC in the home monitoring group compared to the routine [ Time Frame: up to 12 months ]
  3. Days on oral and intravenous antibiotics in the home monitoring group compared to the routine clinical care group [ Time Frame: Up to 12 months ]
  4. Change in body weight in the home monitoring group compared to the routine clinical care group [ Time Frame: Up to 12 months ]
  5. Change in BMI in the home monitoring group compared to the routine clinical care group [ Time Frame: Up to 12 months ]
  6. Change in CFQ-R scores in the home monitoring group compared to the routine clinical care group [ Time Frame: Up to 12 months ]
    The Cystic Fibrosis Questionnaire Revised version (CFQ-R) is a multiple choice and likert questionnaire split into two sections: Demographics and Quality of Life. Answers of 'Always' or similar are deemed a higher value than 'Never' or similar. The total score is gathered by calculating the amount of 'positive' and 'negative' answers - 'positive' answers are those that are lower values (e.g. never) than those that are higher values (e.g. 'always)

  7. Health economic analysis measured by EQ-5D-5L [ Time Frame: Up to 12 months ]
    The Euro Quality of Life (EQ5D) is a multiple choice questionnaire split onto sections including Mobility, Self-Care, Usual activities, Pain/Discomfort, and Anxiety/Depression. For each of these sections, it asks if a person always have issues, some issues or no issues (e.g. Mobility - I have no problems / I have some problems / I am confined to bed). The total score is gathered by calculating the amount of 'positive' and 'negative' answers - 'positive' answers are those that are lower values (e.g. I have no issues) than those that are higher values (e.g. I am confined to bed). There is also a scale, ranging from 0 (worst imaginable health) to 100 (best imaginable health) with 99 intervals in between whereby the patient marks where they feel their current health lays.

  8. Health economic analysis measured by ICECAP-A [ Time Frame: Up to 12 months ]
    The ICEpop CAPability measure for Adults (ICECAP-A) is a multiple choice questionnaire split onto sections including 'Feeling Settled and Secure, Love, Friendship and Support, Being Independent, Achievement and progress, and Enjoyment and pleasure. For each of these sections, it asks whether a person has no problem, some problems, many problems or total problem with a certain area (e.g. Being Independent - I can achieve in all aspects of my life / I can achieve in many aspects of my life / I can achieve in some aspects of my life / I am unable to be at all independent). The total score is gathered by calculating the amount of 'positive' and 'negative' answers - 'positive' answers are those that are lower values (e.g. I can achieve in all aspects of my life) than those that are higher values (e.g. I am unable to be at all independent).

  9. Costs associated with caring for each participant and the cost of conducting the study in the home monitoring group compared to the routine clinical care group [ Time Frame: Up to 12 months ]
  10. Patient experience assessed by a semi-structured qualitative interview in the home monitoring group compared to the routine clinical care group [ Time Frame: Up to 12 months ]
  11. Levels of relevant urine biomarkers in the home monitoring group associated with pulmonary exacerbations [ Time Frame: Up to 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • confirmed diagnosis of CF
  • age over 18 years
  • the requirement for 1 or more admission to hospital to receive intravenous antibiotics over the preceding 24 months
  • clinically stable at the time of recruitment
  • Patients who give informed consent.

Exclusion Criteria:

  • patients who are currently participating in another clinical trial (excluding observational studies)
  • pneumothorax or lung surgery within the previous 3 months, eye surgery (e.g. cataract operation) in the previous 4 weeks (since these factors prevent measurement of spirometry)
  • Sputum infection with Burkholderia cenocepacia or Mycobacterium abscessus
  • Current diagnosis of active allergic bronchopulmonary aspergillosis (ABPA)
  • Previous lung transplantation procedure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02994706


Contacts
Contact: Ed Nash 0121 424 1669 edward.nash@heartofengland.nhs.uk

Locations
United Kingdom
Birmingham Heartlands Hospital Recruiting
Birmingham, West Midlands, United Kingdom, B9 5SS
Contact: Ed Nash    0121 424 1669    edward.nash@heartofengland.nhs.uk   
Principal Investigator: Ed Nash         
Sponsors and Collaborators
Heart of England NHS Trust
National Institute for Health Research, United Kingdom
University of Birmingham
Investigators
Principal Investigator: Edward F Nash, MD Heart of England NHS Foundation Trust

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Heart of England NHS Trust
ClinicalTrials.gov Identifier: NCT02994706     History of Changes
Other Study ID Numbers: 2012135RM
First Posted: December 16, 2016    Key Record Dates
Last Update Posted: February 27, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Fibrosis
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases